# Study of DONQ52 in Active Celiac Disease

> **NCT07239336** · PHASE2 · RECRUITING · sponsor: **Chugai Pharmaceutical** · enrollment: 92 (estimated)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Placebo DONQ52
- **DIETARY_SUPPLEMENT:** Simulated Inadvertent Gluten Exposure (SIGE) capsule
- **DRUG:** DONQ52
- **DIETARY_SUPPLEMENT:** Simulated Inadvertent Gluten Exposure (SIGE) capsule

## Key facts

- **NCT ID:** NCT07239336
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2027-06-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07239336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07239336, "Study of DONQ52 in Active Celiac Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07239336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*